cryoem-ai-drug-design-agent

<!--

COPYRIGHT NOTICE

This file is part of the "Universal Biomedical Skills" project.

Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>

All Rights Reserved.

#

This code is proprietary and confidential.

Unauthorized copying of this file, via any medium is strictly prohibited.

#

Provenance: Authenticated by MD BABU MIA

-->

---

name: 'cryoem-ai-drug-design-agent'

description: 'AI-powered integration of cryo-EM structural data with generative AI and molecular dynamics for structure-based drug design targeting flexible proteins and membrane complexes.'

measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.

allowed-tools:

• read_file
• run_shell_command

---

Cryo-EM AI Drug Design Agent

The Cryo-EM AI Drug Design Agent integrates cryo-electron microscopy structural data with AlphaFold3, generative AI, and molecular dynamics for structure-based drug design. It enables targeting of previously "undruggable" proteins including flexible, membrane-bound, and large macromolecular complexes through high-resolution structure-guided optimization.

When to Use This Skill

• When designing drugs against cryo-EM-solved targets.
• For fragment-based drug discovery with EM structures.
• To model ligand binding in flexible protein regions.
• When targeting membrane proteins and large complexes.
• For integrating AlphaFold predictions with experimental EM density.

Core Capabilities

1. Density-Guided Design: Fit ligands into cryo-EM density maps.

1. AlphaFold Integration: Combine AF3 predictions with EM data.

1. Flexible Docking: Account for protein dynamics in binding.

1. Fragment Screening: Virtual fragment screening with EM structures.

1. Complex Targeting: Design for multi-protein assemblies.

1. Dynamics-Based Design: Incorporate conformational flexibility.

Cryo-EM for Drug Discovery

| Target Class | Cryo-EM Advantage | Drug Discovery Application |

|--------------|-------------------|---------------------------|

| GPCRs | Native lipid environment | Allosteric sites |

| Ion Channels | Multiple conformations | State-specific design |

| Transporters | Conformational states | Mechanism-based |

| Ribosomes | Antibiotic binding | New antibiotics |

| Viral Proteins | Large assemblies | Vaccines, antivirals |

| Intrinsically Disordered | Flexible regions | Challenging targets |

Workflow

1. Input: Cryo-EM density map, protein sequence, ligand/fragment.

1. Structure Refinement: AlphaFold + density-guided refinement.

1. Binding Site Identification: Detect pockets in EM structure.

1. Ligand Placement: Density-guided ligand fitting.

1. MD Simulation: Flexible binding simulation.

1. Optimization: Generative design around hits.

1. Output: Optimized ligands, binding models, design recommendations.

Example Usage

User: "Design ligands for this GPCR cryo-EM structure, accounting for receptor flexibility in the binding pocket."

Agent Action:

python3 Skills/Structural_Biology/CryoEM_AI_Drug_Design_Agent/design_from_cryoem.py \
    --density_map gpcr_3.2A.mrc \
    --protein_sequence gpcr.fasta \
    --alphafold_model gpcr_af2.pdb \
    --resolution 3.2 \
    --ligand_screening fragment_library.sdf \
    --binding_site_residues "3.32,5.46,6.48,7.39" \
    --md_refinement true \
    --generative_optimization true \
    --output gpcr_drug_design/

Input Requirements

| Input | Format | Purpose |

|-------|--------|---------|

| Density Map | MRC/MAP | EM density |

| Protein Sequence | FASTA | AlphaFold input |

| Resolution | Float (Å) | Quality metric |

| Ligand Library | SDF | Virtual screening |

| Known Ligand | Optional SDF | Starting point |

Output Components

| Output | Description | Format |

|--------|-------------|--------|

| Refined Structure | EM + AF combined | .pdb |

| Ligand Poses | Density-fitted poses | .sdf |

| Binding Scores | Affinity predictions | .csv |

| Optimized Compounds | Generative designs | .sdf |

| MD Trajectory | Flexibility analysis | .xtc |

| Design Report | Recommendations | .pdf |

AI/ML Components

Structure Prediction:

• AlphaFold3 for initial model
• Density-guided refinement
• Confidence scoring (pLDDT, local resolution)

Ligand Design:

• Generative AI (diffusion, VAE)
• Reinforcement learning optimization
• Multi-objective scoring

Dynamics Integration:

• Molecular dynamics simulation
• Ensemble docking
• Flexibility-aware scoring

Resolution Considerations

| Resolution | Applications | Limitations |

|------------|--------------|-------------|

| <3.0 Å | Fragment screening, detailed design | Rare |

| 3.0-4.0 Å | Drug optimization, binding mode | Most targets |

| 4.0-5.0 Å | Pocket identification, scaffold | Less detail |

| >5.0 Å | Architecture, general binding | Low for SBDD |

AlphaFold3 + Cryo-EM Integration

| Scenario | Approach | Benefit |

|----------|----------|---------|

| Missing Loops | AF3 prediction | Complete structure |

| Flexible Regions | Ensemble models | Multiple conformations |

| Low Resolution | AF3 template | Higher confidence |

| Ligand Binding | AF3 complex prediction | Binding mode |

Prerequisites

• Python 3.10+
• AlphaFold3, ChimeraX
• GROMACS/OpenMM for MD
• RDKit, AutoDock Vina
• GPU with 16GB+ VRAM

Related Skills

• Time_Resolved_CryoEM_Agent - Dynamics from EM
• PROTAC_Design_Agent - Degrader design
• Molecular_Glue_Discovery_Agent - Glue design
• AlphaFold3_Agent - Structure prediction

Fragment-Based Discovery with Cryo-EM

| Step | Method | Cryo-EM Role |

|------|--------|--------------|

| Fragment Screening | Virtual dock to EM | Density-guided |

| Hit Identification | Cryo-EM soaking | Experimental validation |

| Fragment Growing | EM + modeling | Structure guidance |

| Lead Optimization | Iterative EM | Binding mode confirmation |

Membrane Protein Targets

| Target Type | Cryo-EM Advantage | Examples |

|-------------|-------------------|----------|

| GPCRs | Native membrane | Numerous drugs |

| Ion Channels | State-dependent | Painkillers, antiepileptics |

| Transporters | Mechanism insight | Cancer, infection |

| Receptors | Complex structures | Immunotherapy |

Special Considerations

1. Resolution Limits: Design confidence depends on resolution
2. Map Quality: Local resolution varies across structure
3. Conformational States: Multiple states may be captured
4. Ligand Density: May be weak at lower resolution
5. Validation: Experimental validation essential

Quality Metrics

| Metric | Purpose | Threshold |

|--------|---------|-----------|

| Global Resolution | Overall quality | <4.0 Å for SBDD |

| Local Resolution | Binding site quality | <3.5 Å preferred |

| Map Correlation | Model-to-map fit | >0.8 |

| Real-Space R | Atomic fit | <0.3 |

| Ligand CCC | Ligand fit | >0.6 |

Drug Discovery Success Stories

| Drug | Target | Cryo-EM Role |

|------|--------|--------------|

| Numerous | GPCRs | Structure determination |

| Antibiotics | Ribosome | Binding mode |

| Antivirals | Spike protein | Epitope mapping |

| Various | Ion channels | State-specific design |

Author

AI Group - Biomedical AI Platform

<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->